PD-1 / PD-L1

Scientific explanation

PD-1 on T cells engaging PD-L1/PD-L2 restrains cytotoxic function. Tumour or myeloid PD-L1 is a canonical adaptive immune-evasion axis.

Cancers where relevant

Breast cancer Triple-negative breast cancer Lung cancer Non-small-cell lung cancer Small-cell lung cancer KRAS-driven NSCLC Mesothelioma Colorectal cancer MSI-high colorectal cancer Pancreatic cancer Gastric cancer Esophageal cancer Hepatocellular carcinoma Liver cancer Cholangiocarcinoma Ovarian cancer Cervical cancer Endometrial cancer Uterine cancer Kidney / renal cell carcinoma Bladder cancer Hodgkin lymphoma Glioblastoma Melanoma NRAS-driven melanoma Skin cancers Head and neck cancers

Compounds that intersect this pathway

This oncology atlas is educational. Pathway maps, adjunctive strategies, and compound listings describe mechanistic relevance. They do not establish clinical efficacy, do not recommend treatment, and are not a substitute for oncology care. Evidence tiers are not equivalent.